Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Surprising links between autism, Alzheimer’s could change how we treat both - 2Indian Health Service is digging out of decades-old construction backlog for medical buildings
- 3Zelensky warns of imminent massive Russian attack on Ukraine
- 45 Movies That Leaving an Imprint with Inventive Innovation
- 5Alleged Huione Group Money Laundering Boss Extradited to China
- Huge solar flare no threat to Artemis 2 astronaut launch to the moon, NASA says
- UAE-backed Yemeni Southern Transitional Council denies disbandment rumors
- Move. Cheer. Dance. Do the wave. How to tap into the collective joy of 'we mode'
- Steinmeier honours Italian 'guest workers' who rebuilt German economy
- The Electric Toyota Hilux Is Finally here, But It's Not Cheap
- Starfront Observatories: A haven for distant stargazers
- Practice environmental safety in Style: Divulging Famous Electric Vehicle Brands
- NASA Artemis II tracker: Where is the Orion now and when will it reach the moon?
- What we know about Jonathan Ross, the ICE agent who shot and killed Renee Nicole Good in Minneapolis
